SCHEMBL208366

SCHEMBL208366

FC(F)(F)Oc1cc(Br)ccc1I

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
ALPL P05186 5/20 0.39
HRH4 Q9H3N8 2/20 0.37
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTPN1 P18031 1/20 0.34
SLC6A4 P31645 2/20 0.33
EPHX2 P34913 1/20 0.33
WDR5 P61964 1/20 0.33
KDR P35968 2/20 0.32
ADRA2A P08913 1/20 0.32
PNMT P11086 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29942339 1.00 MAOA (0.40) MAOAMAOBALPLHRH4ALDH1A1
SCHEMBL12782152 0.84 MAPK1 (0.39) MAOAMAOBALPLHRH4ALDH1A1
SCHEMBL4704298 0.81 MAPK1 (0.43) MAOAMAOBALPLHRH4ALDH1A1
SCHEMBL3060730 0.79 MAPK1 (0.41) MAOAMAOBALPLHRH4ALDH1A1
SCHEMBL31373430 0.79 MAPK1 (0.41) MAOAMAOBALPLHRH4ALDH1A1
SCHEMBL30010427 0.78 MAOA (0.43) MAOAMAOBALPLHRH4ALDH1A1
SCHEMBL1337181 0.78 MAOA (0.43) MAOAMAOBALPLHRH4ALDH1A1
SCHEMBL23099860 0.78 GPR3 (0.40) HRH4SLC6A4EPHX2
SCHEMBL213780 0.76 MAOA (0.49) MAOAMAOBALPLHRH4WDR5
SCHEMBL8572781 0.76 ALPL (0.42) MAOAMAOBALPLHRH4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4103557-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12502378-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders JANSSEN PHARMACEUTICA NV (BE) 2025-12-23 US disclosed
EP-4384165-B1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2025-07-09 EP disclosed
US-20240299365-A1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 US disclosed
EP-4384165-A1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS Janssen Pharmaceutica NV (BE) 2024-06-19 EP disclosed
CN-118076351-A Monoacylglycerol lipase modulators for autism spectrum disorders 詹森药业有限公司 2024-05-24 CN disclosed
US-11974987-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders JANSSEN PHARMACEUTICA NV (BE) 2024-05-07 US disclosed
US-20230382902-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-11-30 US disclosed
US-11708359-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-07-25 US disclosed
WO-2023083343-A1 POLYCYCLIC COMPOUNDS AND METHODS THEREOF HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) 2023-05-19 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed
EP-1432693-A2 MCH RECEPTOR ANTAGONISTS Taisho Pharmaceutical Co. Ltd. (JP) 2004-06-30 EP disclosed
US-6673267-B2 EXHIBING HIGH REFRACTIVE INDEX ANISOTROPY; PHOTOSTABILITY; USEFUL IN PRODUCING COLORED FILMS, DISPLAYS, OPTICAL RECORDING MATERIALS, OPTICAL COMPENSATORS, POLARIZERS, REFLECTOR PLATES, AND SCATTERING PLATES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-01-06 US disclosed
WO-2003028641-A2 MCH RECEPTOR ANTAGONISTS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-04-10 WO disclosed
US-6387903-B1 ANTICANCER AGENT; CARDIOVASCULAR DISORDERS; VIRICIDES MERCK & CO., INC. 2002-05-14 US disclosed
US-20020006479-A1 Phenylacetylene compound, liquid crystal composition, polymer, optically anisotropic product, and liquid crystal or optical element SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-01-17 US disclosed
US-6090805-A Tocolytic oxytocin receptor antagonists MERCK & CO., INC. (US) 2000-07-18 US disclosed
EP-1014984-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2000-07-05 EP disclosed
US-5968938-A Piperazine oxytocin receptor antagonists MERCK & CO., INC. (US) 1999-10-19 US disclosed
WO-1999009985-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11974987-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders LIPC, LPL, MGLL MAOA 113/4885MAOB 62/4885ALPL 2676/4885
US-20240299365-A1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS LIPC, LPL, MGLL MAOA 113/4885MAOB 62/4885ALPL 2676/4885
US-11708359-B2 Monoacylglycerol lipase modulators MGLL, LPL, LIPC MAOA 155/4885MAOB 62/4885ALPL 2221/4885
US-20230382902-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, LIPC MAOA 155/4885MAOB 62/4885ALPL 2221/4885
US-12502378-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders LIPC, LPL, MGLL MAOA 113/4885MAOB 62/4885ALPL 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.